Aquestive Therapeutics, Inc. SEC filings AQST
Aquestive Therapeutics, Inc. has 686 filings in SEC EDGAR's recent list, going back to May 14, 2007. Its latest annual report, Form ARS, was filed on Apr 24, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Jul 8, 2026 | — |
| EFFECT | Filing | Apr 23, 2024 | — |
| CORRESP | Letter to the SEC | Apr 19, 2024 | — |
| CORRESP | Letter to the SEC | Apr 19, 2024 | — |
| CORRESP | Letter to the SEC | Apr 16, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 8, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 19, 2023 | — |
| CORRESP | Letter to the SEC | Dec 13, 2023 | — |
| UPLOAD | Letter from the SEC | Oct 27, 2023 | — |
| EFFECT | Filing | Sep 29, 2023 | — |
| CORRESP | Letter to the SEC | Sep 27, 2023 | — |
| UPLOAD | Letter from the SEC | Sep 25, 2023 | — |
| CT ORDER | Filing | Sep 22, 2021 | — |
| EFFECT | Filing | Apr 5, 2021 | — |
| CORRESP | Letter to the SEC | Apr 1, 2021 | — |
| UPLOAD | Letter from the SEC | Mar 31, 2021 | — |
| EFFECT | Filing | Jan 19, 2021 | — |
| CORRESP | Letter to the SEC | Jan 14, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 13, 2021 | — |
| EFFECT | Filing | Sep 17, 2019 | — |
| UPLOAD | Letter from the SEC | Sep 16, 2019 | — |
| CORRESP | Letter to the SEC | Sep 16, 2019 | — |
| CT ORDER | Filing | Jul 25, 2018 | — |
| EFFECT | Filing | Jul 24, 2018 | — |
| CERT | Filing | Jul 24, 2018 | — |
| CORRESP | Letter to the SEC | Jul 23, 2018 | — |
| CORRESP | Letter to the SEC | Jul 23, 2018 | — |
| 8-A12B | Form 8-a12b | Jul 20, 2018 | — |
| CORRESP | Letter to the SEC | Jul 20, 2018 | — |
| UPLOAD | Letter from the SEC | Jul 19, 2018 | — |
| CORRESP | Letter to the SEC | Jul 12, 2018 | — |
| CORRESP | Letter to the SEC | Jul 11, 2018 | — |
| CORRESP | Letter to the SEC | Jun 28, 2018 | — |
| CORRESP | Letter to the SEC | Jun 27, 2018 | — |
| UPLOAD | Letter from the SEC | Jun 8, 2018 | — |
| DRSLTR | Filing | May 22, 2018 | — |
| DRS/A | Filing | May 22, 2018 | — |
| D | Filing | May 9, 2018 | — |
| UPLOAD | Letter from the SEC | Apr 26, 2018 | — |
| DRS | Filing | Apr 2, 2018 | — |
| RW | Filing | Mar 27, 2008 | — |
Showing 41 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AQST (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Warren, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1398733
- Former names
- MonoSol Rx, Inc. (until Mar 27, 2008)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.